Agenus: Advancement Of Botensilimab Could Create A Great Pivot Point

Dec. 13, 2022 5:57 AM ETAgenus Inc. (AGEN)BMY, BMYMP, INCY, MRK6 Comments


  • Focus still remains on advancing balstilimab, but instead of just using it alone as a monotherapy against advanced cancers, it is being moved forward together with botensilimab.
  • The phase 2 ACTIVATE program will use botensilimab either alone or in combination with balstilimab for the treatment of patients with microsatellite stable colorectal cancer, melanoma, and pancreatic cancer.
  • The prior study established proof of concept in using botensilimab in combination with balstilimab to treat patients with advanced refractory cancers.
  • Agenus has developed several partnerships for in-house developed drugs to be used with other immunotherapies to treat patients with advanced refractory cancers. Partnerships include Merck, Bristol Myers Squibb, and Incyte.
  • Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »

3D pink collagen

wangmando/iStock via Getty Images

Agenus (NASDAQ:AGEN) is a great speculative biotech play to look into. The reason why I state that is because it has great potential on its pivot more towards advancing an anti-CLTA-4 therapy known as botensilimab. It

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis profile picture
Actionable ideas on small-large cap biotech stocks through deep analysis.

I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha.

You can follow me on under the name BiopharmaPro where I currently have (62.5K) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.